Overview

This trial is active, not recruiting.

Conditions carotid artery diseases, stroke
Treatment carotid artery stent
Phase phase 3
Sponsor Gardia Medical
Start date February 2013
End date April 2014
Trial size 240 participants
Trial identifier NCT01783639, WIRION Study Europe (WISE), WIRION™ Pivotal Study (WISE)

Summary

The purpose of this study is to compare the safety and performance of WIRION™ EPD in patients undergoing carotid artery stenting to a performance goal based on an analysis of the results of previous US IDE carotid stenting with embolic protection studies

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose prevention
Arm
(Experimental)
Device: WIRION™ Embolic Protection System Interventions: Carotid Artery Stent
carotid artery stent
Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices

Primary Outcomes

Measure
The rate of peri-procedural (within 30 days of procedure) death, stroke, and myocardial infarction.
time frame: Within 30 Days of procedure

Secondary Outcomes

Measure
The rate of Device Success
time frame: Participants will be followed for the duration of the procedure, an expected average of 35 minutes
The rate of Clinical Success
time frame: Participants will be followed for the duration of the procedure, an expected average of 35 minutes
The rate of Access site complications
time frame: Within 30 Days of procedure
Neurological events occurring within 30 days post procedure,including strokes and transient ischemic attacks
time frame: Within 30 Days of procedure
Angiographic Success
time frame: Participants will be followed for the duration of the procedure, an expected average of 35 minutes
Procedural Success
time frame: Participants will be followed for the duration of the procedure, an expected average of 35 minutes

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - 18 years of age - Anticipated patient life expectancy of at least 1 year - Patient or authorized representative, signed a written Informed Consent form - Patient is willing to comply with the protocol requirements - Candidate for catheter-based therapy of a single stenosis located in the internal carotid artery (ICA) or the carotid bifurcation, suitable for treatment with a single FDA-approved stent with a carotid use indication - Reference vessel diameter for intended filter location between 3.5mm and 6.0mm - An adequate "landing zone" of at least 30mm - Patients with severe symptomatic or asymptomatic carotid artery stenosis, to be ≥ 50% for symptomatic patients OR ≥ 80% for asymptomatic patients - At least one high surgical risk criteria, either anatomical or co-morbid risk factors, as listed below: Category I - Anatomical high risk factors - Recurrent stenosis after endarterectomy - Previous radical neck surgery or radiation therapy to the neck - High cervical ICA lesions or CCA lesions at or above C2 or below the clavicle - Spinal immobility of the neck - Tracheostomy or tracheal stoma - Any laryngeal nerve palsy and bilateral carotid artery stenosis Category II - Co-morbid risk factors - Contralateral carotid occlusion - Unstable angina (Canadian Cardiovascular Society class III/IV) - Congestive Heart Failure (New York Heart Association functional class III/IV) and/or known severe left ventricular dysfunction LVEF<30% - Requires coronary artery bypass surgery, cardiac valve surgery, major vascular surgery, or abdominal aortic aneurysm repair 31-60 days post carotid stent procedure - Recent MI (>72 hr and <4 weeks) - Severe pulmonary disease with FEV1 of <30% - CAD in ≥2 unrevascularized vessels with stenosis ≥70% - Age ≥75 years - Uncontrolled diabetes - Female patient with no child bearing potential or has negative pregnancy test within the previous 7 days and agrees to remain on birth control throughout the study Exclusion Criteria: - Total occlusion or near-occlusion of the target vessel - Severe lesion calcification - Presence of an alternate source of emboli - Presence of a filling defect, or angiographically visible thrombus, at target site - A greater than 50% CCA lesion proximal to the target or a distal (intracranial) lesion more severe than the target lesion - Evolving, acute or recent stroke within the last 30 days - Major stroke with a residual neurological deficit that would confound neurologic assessment - Vertebrobasilar insufficiency symptoms only - Major operation 30 days before or after the index procedure - Ipsilateral intracranial stenosis that requires treatment - Any pre-existing stent in ipsilateral carotid artery, or placement of a stent in contralateral carotid within 30 days of the index procedure - History of intracranial hemorrhage within 12 months - Any condition that precludes proper angiographic assessment or prevents femoral arterial access - Uncontrolled hypertension - Contraindication to heparin and bivalirudin, aspirin, thienopyridines - Known sensitivity to radiographic contrast media which cannot be controlled with pre-medication - History or current indication of bleeding diathesis or coagulopathy - Chronic renal insufficiency - Carotid artery dissection or aortic arch anatomical anomalies - Dementia or a neurological illness - Patient is enrolled in another drug or device study protocol that has not reached its primary endpoint - Severe pulmonary hypertension - Intra-cranial pathology (e.g., tumor, AVM. aneurysm, etc) that would make study participation inappropriate or confound neurologic assessment

Additional Information

Official title The WISE Study is a Pivotal Study Evaluating the Safety and Performance of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting
Principal investigator Dierk Scheinert, MD
Description Patient registry procedures include: - Clinical Events Committee (CEC); responsibility for validating all reported primary safety outcomes - Data Safety Monitoring Board (DSMB); to review and evaluate safety data including serious adverse events - 100% data monitoring; to compare data entered into the registry - Source data verification; to assess the accuracy, completeness of registry data by comparing the data to external data sources (e.g., medical records, paper or electronic case report forms). - Standard Operating Procedures; to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis and reporting for adverse events. - Sample size assessment to specify the number of participants and follow up duration. - Data Management Plan; to address situations where variables are reported as missing, unavailable, "non-reported," uninterpretable, or considered missing because of data inconsistency or out-of-range results - Statistical analysis plan; describing the analytical principles and statistical techniques to be employed in order to address the primary and secondary objectives, as specified in the study protocol or plan.
Trial information was received from ClinicalTrials.gov and was last updated in March 2014.
Information provided to ClinicalTrials.gov by Gardia Medical.